Novel transfecting assemblies comprising biotinylated cationic liposomes, DNA and tribiotinylated transferrin-streptavidin (streptavidin(bio3-transferrin)) accessories have been prepared, characterized and evaluated for toxicity and DNA delivery capability in human cervical carcinoma cells (HeLa). Two new lipophilic cholesteryl-based biotin derivatives, biotinylcholesterylformylhydrazide (MSB1) and aminohexanoylbiotinylcholesterylformylhydrazide (MSB2) provided docking points for streptavidin(bio3-transferrin) on cationic liposomes which were formulated with N,N-dimethylaminopropylaminylsuccinylcholesterylformylhydrazide (MS09) and dioleoylphosphatidylethanolamine (DOPE) in a 2:48:50 molar ratio. Ethidium dye displacement assays and gel retardation studies suggest that in ternary complexes, the DNA is electrostatically bound to the cationic liposomes while transferrins remain liposome-bound through streptavidin-biotin interactions. Assemblies fully protected plasmid DNA from serum nuclease digestion over a range of liposome:pGL3 DNA ratios (3-8:1, w/w) and exhibited low growth inhibition of HeLa cells (circa 5%) at the optimal transfection composition for streptavidin(bio3-transferrin):liposome:pGL3 DNA of 10:6:1 (w/w/w). Transfection levels, which were twice those of untargeted lipoplexes containing MSB1 or MSB2, were not significantly diminished in the presence of 10% foetal bovine serum. Excess transferrin (200 microg per well) reduced transfection levels to those of untargeted complexes, supporting the notion that at least 50% of ternary complexes gained entry into the cervical carcinoma cells by receptor mediation. Conversely, transfection levels with untargeted lipoplexes were only slightly reduced in the presence of transferrin at the same concentration.